{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F36d890cb-d33f-4292-a3e5-0faf480c00bc","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Optimizing the Identification of HER2-Low Breast Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/36d890cb-d33f-4292-a3e5-0faf480c00bc\"></iframe>","title":"Optimizing the Identification of HER2-Low Breast Cancer","description":"\n        <p>Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayTestingHER2LowBC24\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/9fd1cf5d-aca7-4674-b0d9-7f7c93c26dd7/cover.jpg"}